Which factors influence psychiatric diagnosing in substance abuse treatment?

International Journal of Mental Health Systems

Ellen Hoxmark²  Anne Landheim¹  Rolf Wynn² 

[1] Innlandet Hospital Trust, Ottestad, N-2312, Norway;Department of Clinical Medicine, University of Tromsø, Tromsø, N-9037, Norway

关键词: MINI-Plus;    Diagnostic practice;    Substance use disorders;    Co-occurring disorders;   

Others  :  801570
DOI  :  10.1186/1752-4458-7-17

 received in 2012-11-28, accepted in 2013-05-30,  发布年份 2013

【 摘 要 】

Background

The importance of diagnosing and treating co-occurring psychiatric disorders among substance abusers in treatment has received much attention. The aim of this study was to investigate to which extent co-occurring psychiatric disorders are diagnosed in a clinical population of substance abusers, and which factors (including the use of MINI-Plus) that influence the diagnosing of co-occurring psychiatric disorders.

Methods

Patients (N = 275) who received inpatient substance use treatment in five different units in Northern Norway participated in the study. The patients’ clinicians gave information on diagnoses given during the stay in the units, and whether a systematic diagnostic tool was used for the diagnosing (MINI-Plus). Predictors of independent co-occurring psychiatric disorders were examined utilizing hierarchical regression analysis.

Results

One third of the patients were given an independent psychiatric diagnosis. Less than half of the patients were assessed using a diagnostic tool. The main predictor of diagnosing of independent psychiatric disorders was the use of the diagnostic tool MINI-Plus. Younger patients and patients that used less alcohol, were given independent psychiatric diagnoses more frequently.

Conclusions

The number of co-occurring independent psychiatric diagnoses was lower compared to other studies using standardized diagnostic tools. The low number of patients assessed by such a tool, and the strong relationship between the use of such a tool and the diagnosing of co-occurring psychiatric disorders, suggest that the implementation of standardized diagnostic tools should be addressed in the units. Generally, patients suffering from substance use disorders should be systematically screened for other psychiatric disorders, in order to improve their treatment and health.

【 授权许可】

   
2013 Wynn et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mueser KT, Noordsy DL, Drake RE, Fox L: Integrated treatment for dual disorders: a guide to effective practice. New York: The Guildford Press; 2003.
• [2]Kelly TM, Daley DC, Douaihy AB: Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 2012, 37:11-24.
• [3]Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
• [4]Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al.: 12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004, 109:28-37.
• [5]Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al.: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004, 61:807-816.
• [6]Kessler RC, Chiu WT, Demler O, Walters EE: Prevalence, severity, and comorbidity of 12-Month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
• [7]Hasin D, Liu X, Nunes E, McCloud S, Samet S, Endicott J: Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry 2002, 59:375-380.
• [8]Jané-Llopis E, Matytsina I: Mental health and alcohol, drugs and tobacco: a review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug Alcohol Rev 2006, 25:515-536.
• [9]Ross HE, Glaser FB, Germanson T: The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry 1988, 45:1023-1031.
• [10]Landheim AS, Bakken K, Vaglum P: Sammensatte problemer og separate systemer. Psykiske lidelser blant rusmisbrukere til behandling i russektoren (Complex problems and separate systems. Psychiatric illness among substance abusers in substance abuse treatment). Nor Epidemiol 2002, 12:309-318.
• [11]Wynn R: Prior psychotic episodes among patients in a substance abuse clinic. J Subst Use 2007, 12:127-132.
• [12]Verheul R: Patients with addiction and personality disorder: treatment outcomes and clinical implications. Curr Opin Psychiatry 2007, 20:67-71.
• [13]O’Brien CP, Charney DS, Lewis L, Cornish JW, Post RM, Woody GE, et al.: Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action. Biol Psychiatry 2004, 56:703-713.
• [14]Hailemariam S, Tessema F, Asefa M, Tadesse H, Tenkolu G: The prevalence of depression and associated factors in Ethiopia: findings from the National Health Survey. Int J Ment Health Syst 2012, 6:23. BioMed Central Full Text
• [15]Marshall BDL, Werb D: Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction 2010, 105:991-1002.
• [16]Conner KR, Pinquart M, Holbrook AP: Meta-analysis of depression and substance use and impairment among cocaine users. Drug Alcohol Depend 2008, 98:13-23.
• [17]Conner KR, Pinquart M, Gamble SA: Meta-analysis of depression and substance use among individuals with alcohol use disorders. J Subst Abuse Treat 2009, 37:127-137.
• [18]Landheim AS, Bakken K, Vaglum P: Gender differences in the prevalence of symptom disorders and personality disorders among poly-substance abusers and pure alcoholics. Substance abusers treated in two counties in Norway. Eur Addict Res 2003, 9:8-17.
• [19]Goodwin RD, Stein DJ: Anxiety disorders and drug dependence: Evidence on sequence and specificity among adults. Psychiatry Clin Neurosci 2013, 67:167-73.
• [20]Myrick H, Brady K: Current review of the comorbidity of affective, anxiety, and substance use disorders. Curr Opin Psychiatry 2003, 16:261-270.
• [21]Nunes EL, Levin FR: Treatment of depression in patients with alcohol and other depression. JAMA 2004, 291:1887-1896.
• [22]Carroll KM, Rounsaville BJ, Gordon LT, Nich C, Jatlow P, Bisighini RM, et al.: Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry 1994, 51:177-187.
• [23]Husband SD, Marlowe DB, Lamb RJ, Iguchi MY, Bux DA, Kirby KC, et al.: Decline in self-reported dysphoria after treatment entry in inner-city cocaine addicts. J Consult Clin Psychol 1996, 64:221-224.
• [24]Brown SA, Schuckit MA: Changes in depression among abstinent alcoholics. J Stud Alcohol 1988, 49:412-417.
• [25]Strain EC, Stitzer ML, Bigelow GE: Early treatment time course of depressive symptoms in opiate addicts. J Nerv Ment Dis 1991, 179:215-221.
• [26]Nunes EL, Sullivan M, Levin FR: Treatment of depression in patients with opiate dependence. Biol Psychiatry 2004, 56:793-802.
• [27]Brown SA, Irwin M, Schuckit M: Changes in anxiety among abstinent male alcoholics. J Stud Alcohol 1991, 52:55-61.
• [28]Greenfield SF, Weiss RD, Muenz LR, Vagge LM, Kelly JF, Bello LR, et al.: The effect of depression on return to drinking: A prospective study. Arch Gen Psychiatry 1998, 55:259-265.
• [29]Fridell M, Hesse M: Psychiatric severity and mortality in substance abusers: A 15-year follow-up of drug users. Addict Behav 2006, 31:559-565.
• [30]Chan YF, Dennis ML, Funk RR: Prevalence and comorbidity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment. J Subst Abuse Treat 2008, 34:14-24.
• [31]Gråwe R, Ruud T: Rus og psykiske lidelser i psykisk helsevern for voksne. (Substance use and mental disorders in adult mental treatment in Norway) (Rep. No. STF78 A06003). SINTEF Helse: Oslo/Trondheim; 2006.
• [32]Weiss RD: Identifying and diagnosing co-occurring disorders. CNS Spectr 2008, 13:4-6.
• [33]Wynn R, Karlsen K, Lorntzsen B, Bjerke TN, Bergvik S: Users and GPs causal attributions of illegal substance use: An exploratory interview study. Patient Educ Couns 2009, 76:227-232.
• [34]Hoxmark E, Nivison M, Wynn R: Predictors of mental distress among substance abusers receiving inpatient treatment. Subst Abuse Treat Prev Policy 2010, 5:15. BioMed Central Full Text
• [35]Hoxmark E, Benum V, Friborg O, Wynn R: Reduction in mental distress among substance users receiving inpatient treatment. Int J Ment Health Syst 2010, 4:30. BioMed Central Full Text
• [36]Sletteng R, Harnang AK, Hoxmark E, Aslaksen PM, Friborg O, Wynn R: A Psychometric study of the drug use disorders identification test - Extended in a Norwegian sample. Psychol Rep 2011, 109:663-674.
• [37]Hoxmark E, Wynn TN, Wynn R: Loss of activities and its effect on the well-being of substance abusers. Scand J Occup Ther 2012, 19:78-83.
• [38]Høye A, Rezvy G, Hansen V, Olstad R: The effect of gender in diagnosing early schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2006, 41:549-555.
• [39]Andreassen M, Seloter PB: Pasientstrømmen til tverrfaglig spesialisert rusbehandling i Nord-Norge (Admission to multidisciplinary specialized substance abuse treatment in Northern Norway). Narvik, Norway: Nordnorsk kompetansesenter-Rus; 2005.
• [40]World Health Organization: The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. 10th edition. Geneva: World Health Organisation; 1992.
• [41]Strand BH, Dalgard OS, Tambs K, Rognerud M: Measuring the mental health status of the Norwegian population: A comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry 2003, 57:113-118.
• [42]Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L: The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974, 19:1-15.
• [43]Lipman RS, Covi L, Shapiro AK: The Hopkins Symptom Checklist (HSCL): Factors derived from the HSCL-90. J Affect Disord 1979, 1:9-24.
• [44]Saunders JB, Aasland OG, Babor TF, De La Fuente JR, Grant M: Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction 1993, 88:791-804.
• [45]Berman AH, Bergman H, Palmstierna T, Schlyter F: Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res 2005, 11:22-31.
• [46]Iversen E, Lauritzen G, Skretting A, Skutle A: Klientkartleggingsdata: rapport for 2008 (Client data: report 2008). Bergen, Norway: Stiftelsen Bergensklinikkene and Statens institutt for rusmiddelforskning; 2009.
• [47]Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al.: The Mini-International Neuropsychiatric Interview (M.I.N.I): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59:22-33.
• [48]Gunter TD, Arndt S, Wenman G, Allen J, Loveless P, Sieleni B, et al.: Frequency of mental and addictive disorders among 320 men and women entering the Iowa Prison System: Use of the MINI-Plus. J Am Acad Psychiatry Law 2008, 36:27-34.
• [49]Hoxmark E, Wynn R: Health providers’ descriptions of the significance of the therapeutic relationship in treatment of patients with dual diagnoses. J Addict Nurs 2010, 21:187-193.
• [50]Hasin DS, Stinson FS, Ogburn E, Grant BF: Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007, 64:830-842.
• [51]Kranzler HR, Kadden RM, Burleson JA, Babor TF, Apter A, Rounsaville BJ: Validity of psychiatric diagnoses in patients with substance use disorders: Is the interview more important than the interviewer? Compr Psychiatry 1995, 36:278-288.
• [52]Langås AM, Malt UF, Opjordsmoen S: Comorbid mental disorders in substance users from a single catchment area - a clinical study. BMC Psychiatry 2011, 11:25. BioMed Central Full Text
• [53]Gossop M, Marsden J, Stewart D: Remission of psychiatric symptoms among drug misusers after drug dependence treatment. J Nerv Ment Dis 2006, 194:826-832.